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Editorial Message
Our Journal, now in its third year, has earned for itself a
reputation of being the fastest forum for disseminating
the results of research on inflammation processes, in
particular within the field of mediators. This field contin-
ues to undergo a spectacular growth in several directions
(immunopathology, allergology, joint conditions, pul-
monary disorders, transplantation etc.), all of which are
well represented in reviews and research articles of
Mediators of Inflammation. Increased knowledge about
mediators has also a considerable impact on finding and
developing improved drugs for treating the above condi-
tions. Accordingly, articles dealing with this theme would
be particularly welcome in our Journal. To this end we
invited Professor. H. Timmerman, a leading expert in
pharmacochemistry and drug development, to put for-
ward his personal view on this subject. We hope that this
Debate Article will precipitate a response from research
workers of the pharmaceutical industry. Responses to
this article and/or other submissions around this subject
would be encouraged by the Editors.
A,pessimistic view on the future
of drugs" pharmapolicy determines
whether new drugs will become
available
H. Timmerman
Leiden/Amsterdam Center for Drug Research,
Vrije Universiteit, Department of
Pharmacochemistry, De Boelelaan 1083,
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Throughout the existence of mankind, there has
been a need for treatingmand if possible, for
curing--diseases. One of the most explored possi-
bilities is treatment by means of medicinal agents.
Traditionally, medicinal agents were found in natural
sources, mainly in plants, but, occasionally, such
products were obtained from animals. A number of
so-called modern therapeutics have a long history
and have been developed from traditional medi-
cines; some very well-known examples are acetylsali-
cylic acid; the heart glycosides, such as digitoxin; and
the anticancer drug, etoposide.
Only relatively late in history were medicinal
agents selected on the basis of certain properties
of the preparation itself or its source. A well-known
example is the use of the mandrake; this plant
has roots the shape of which has something in
common with the shape of the human body; this
fact was sufficient to consider it a cure for any kind
of ailment.
Increasing insight into the functioning of the hu-
man body and the causes of disease have allowed us
to develop more effective drugs. One limiting factor
has often been the inadequate knowledge of what
we now call ’pure’ chemical products. Until about
1850 chemistry was dominated by inorganic and
analytical chemistry. Chemicals which were applied
as drugs were, accordingly, inorganic compounds.
Such compounds (especially metal oxides) are gen-
erally rathertoxic and produce mainly signs of
toxicity, making believe that the treatments were
effective. The tradition of using these inorganic
substances led people such as Paracelsus and
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Hahnemann to advocate the use of highly diluted
preparations, which eventually led to the develop-
ment of the homeopathic principle. The principle of
agents that worked but not helped has in the course
of time been transferred into the use of preparations
that sometimes helped, but not worked.
Around 1850 synthetic organic chemistry started to
develop. At almost the same time experimental phar-
macology was introduced, and therefore the hope
for new medicines became extremely high at that
time. For the first time chemistry played its own role
in the development of new drugs.
From 1850 onwards chemists made large numbers
of new organic compounds. Pharmacologists estab-
lished whether these substances, when administered
to animals, caused any effects which could be of
potential interest for influencing a certain physiologi-
cal function and which, subsequently, could be re-
garded as a cure for a certain disease. This procedure
(synthesizing and ’screening’) was scientifically not
very appealing, but did lead to a large number of
highly effective medicines, some of which are still in
use. In this way the first antihistamines (Hi-blockers),
the anti-allergic drug cromoglycate and the non-
steroidal anti-inflammatory drugs (NSAIDs) have
been developed. Such developments have been, and
still are, important for pharmacotherapy, but they
have also contributed enormously to our current
knowledge of physiological and pathological pro-
cesses. The best example within the field of inflam-
mation is probably the NSAIDs; the availability of a
drug such as aspirin made possible the unravelling of
the arachidon cascade.
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During the second half of the nineteenth century
several scientists predicted that soon insight into
structure-activity relationships would allow the de-
sign of very selective drugs for virtually all ailments.
It was not long before it became clear that these
predictions had no value. The gimple reason was, of
course, that the physiology of the human body is
complex, which makes it rather difficult to reach
selectivity. In the 1930s the famous pharmacologist
Clark sighed that the knowledge on drug activity was
still very limited and that the only positive.thing was
that scientists were aware of their ignorance in
this respect.
However, since the turn of the century the ideas
about the mechanisms involved in drug actions had
changed; the receptor concept was introduced
(Langley, Ehrlich). In the 1930s Clark proposed his
so-called ’occupancy theory’: the effect of a drug is
determined by the level of occupation of the receptor
by the drug.
It was not until the 1950s and 1960s that really new
approaches emerged. In this period pharmacology
became a molecular science. In particular, the re-
search group of Ariens showed the advantages of
tests in which direct interaction between a drug and
its receptor could be established and which allowed
a simple numerical value for biological activity to be
obtained. The publication in 1964 of Ariens’ book
MolecularPharmacology is to be considered a mile-
stone in the history of drug research.
Another major development concerns the intro-
duction of computers. The use of computers enabled
the calculation of quantitative equations in which a
given biological activity of individual members of a
series of chemically and pharmacologically related
substances is related with, for example, parameters
that describe the chemiCal and physical properties
of the compounds. The so-called method of multi-
regression analysis, introduced in 1961 by Hansh,
to calculate quantitative structure-activity relation-
ships (QSARs) is as important as the change of
pharmacology into pharmacological science.
From the 1960s onwards the search for new me-
dicinal agents started with the concept of a mech-
anism of action. The search was not simply for an
antihypertensive, but for an adrenoceptor blocker;
not just for an antiasthmatic, but for an inhibitor of
the release of histamine from mast cells. Since then
several new types of drugs have been developed,
e.g. 2-agonists and Il-antagonists, H,.-blockers, ACE-
inhibitors, and proton-pump-blockers.
The trend which developed strongly since then
was the need for high selectivity and low toxicity. An
extremely nice example of increased selectivity is the
development of I,.-agonists for treating asthma. The
old adrenergic agonist ephedrine (from a traditional
Chinese preparation) is an effective bronchodilator
(via I,.-receptors, as we know now), but has serious
side-effects. It reaches the brain (stimulating
potentials for addiction), it is hypertensive (0q) and
increases the heart frequency (1). Adrenaline, which
was later introduced, has no CNS effects (does not
reach the brain), but still has other drawbacks. With
isoprenaline (no Otl-effect) the effects on the blood
pressure were abolished and the subsequent devel-
opment of salbutamol (no CNS penetration, no 0tl, no
[) as a pure 12-agonist led to a compound with still
the same main effects as ephedrine, without any of
its major side effects, however.
Other examples are the effective and selective
antiviral agents (only viricidal in infected cells as the
given compound is activated by an enzyme which is
introduced by the virus itself), the new selective
serotonin agonists (like sumatriptan) or the inhibitors
of the H+K/ATP-ase (omeprazole); many other exam-
ples could be given.
It is very difficult to design non-toxic com-
pounds. A major reason is that toxicity is almost
always caused by several interactions between the
compound (or its metabolites) and the biological
system, whereas, in ideal cases, a pharmacological
effect is monofactorial. However, the recent develop-
ment of toxicology into a molecular science (just as
happened with pharmacology earlier) will surely
contribute to the possibilities of designing better
medicines.
Currently, two major new trends are becoming
more and more important: the use of the ’big’ com-
puters and the application of the techniques of mo-
lecular biology. Nowadays, computers are much
more than just instruments for complicated calcula-
tions. The application of computer graphics to visu-
alize the 3D-structure of receptors (e.g. enzymes,
obtained by crystallization) and the interaction ot: the
medicinal agent with the receptor is very attractive
for designing better molecules (lead optimalization).
These days it is still necessary to have a lead structure
but it is expected that it will not take long before it
is possible, when the structure of the receptor is
available, to have completely new structures gener-
ated by the computer (lead generation).
The importance of molecular biology for drug
research seems to have been overestimated in the
1980s. Some years ago it was believed that the future
of medicinal treatment was in the hands of molecular
biology. Now we know that this was a wrong con-
clusion. A research director of a pharmaceutical com-
pany once said during a symposium, ’The application
of molecular biology will not lead to really new
drugs, as molecular biology concerns processes, not
products’. The significance of molecular biology,
however, can easily be underestimated as well. The
application of molecular biology contributes in sev-
eral ways to drug research.
Insight into biological processes, both physio-
logical and pathological
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Elucidation of the structure of receptors; detec-
tion of ’new’ receptors.
Production of antibodies (therapy, targeting,
vaccines).
Introduction of gene therapy.
Thanks to the results from molecular biological
investigations we know now much more about
the structure of receptors, the signal transfer mech-
anisms, the de- and resensitization events and
the so-called cross-talk between different receptor
systems.
Taking all things together it seems that perspec-
tives for the development of new drugs have never
been as bright as they are now. So, one would think
that it should be rather easy to predict a very bright
future for those who want to develop new drugs, and
possibly also to indicate which type of drugs might
be expected.
Unfortunately, both thoughts are not true. To
start with the second one, in the 1970s the
results of a so-called Delphi investigation predicted
which developments were expected to take place in
biomedical sciences, especially in pharmacotherapy.
Several predictions were correct (a vaccine against
measles, better fibrinolytics, no real progress in treat-
ing allergies). Other predictions, however, were
absolutely wrong (a vaccine against the common
cold, improved therapy for multiple sclerosis, a
contraceptive for males). However, it is frustrating
to see that several major developments were
not foreseen (the report even lacks words like
’molecular biology’, ’DNA recombinant techniques’,
’prostaglandins’, ’Ha-receptor antagonists’, ’ACE-
blockers’, ’proton-pump-blockers’, ’AIDS’, ’peni-
cillinase inhibitors’).
In fact, during a major conference in London
in 1978 it was concluded that medicines had no
future at all--and that was when products such as
cime-tidine, ranitidine, omeprazole and lovastatin
were still to be introduced in pharmacotherapy! So it
seems very difficult indeed to make predictions in
this field.
But it is also not justified to predict a bright future
for new drugs in general. Most new drugs, in fact
almost all, are developed by pharmaceutical indus-
tries. The future of the pharmaceutical industry, how-
ever, is not certain internationally. The main reasons
for this uncertainty are simple:
the financial situation deteriorates (reduced con-
sumption of medicines, lowered prices and profit
margins);
the costs of developing a new drug continue to
increase (reduced number of ’hits’, requirements
more severe).
This situation will eventually lead to:
a reduction in the number of innovating
industries (stronger and on a shorter term than
expected previously);
a situation in which each industry will try to
present its new product as ’unique’ (delay of
publishing to avoid the development of early
second generation products by competitors,
strengthening the monopolistic position);
a monopolistic position of industries.
In particular, the delay in publishing data on
new developments and key structures will be
counter-productive for science and for the perspec-
tives of the pharmaceutical industries in the long
term. Clearly, these developments have several
causes: the costs for health care are considered to be
too high, drug prices should be reduced and
drug consumption should be diminished. The indus-
tries (both the national associations and the
individual houses) defend their position. The way
the industries do so is not always easy to follow;
they never succeeded to explain clearly, for example,
why important price differences for the same
drug exist in different countries. Regrettably, the
action and reaction situation might lead to a mo-
nopolistic position of a very limited number of indus-
tries indeed. The rapid disappearance of the large
group of relatively small innovating industries will
be regretted in due time, but at that time it will be
too late. It is this last type of industry which
has contributed extensively to the development Of
second generation drugs, drugs which often
show important advantages over the first developed
compounds in the given class; moreover, such
second generation drugs have a role in making the
prices competitive.
But, as every cloud has a silver lining, the situation
which emerges now could mean that complex mol-
ecules such as peptides would have better chances,
as such derivatives reach the mark ’unique’ relatively
easily. As only these unique products will be allowed
to have a high price, such products might become
worthwhile developing. These situations open good
perspectives especially for peptides involved in im-
munology, allergy, inflammation and related dis-
eases; of course, major problems (e.g. of pharma-
cokinetic nature) connected with the use of peptides
should be solved.
In the longer term, however, pessimism should
dominate. The costs involved with the development
of any drug are extremely high. Any company can
develop a new drug (including the unique ones, with
a high price) only if the return on investment is
guaranteed; the large amounts of money needed for
developing new drugs can only arise from best-
selling drugs (sometimes at prices that seem very
high for lay people). As only a few companies will
be able to develop such best-sellers, the conclusion
can only be that the recent attitude of virtually all
national governments to reduce drug consumption
will eventually lead to a very strongly reduced rate of
development of new drugs. This is a pessimistic
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point-of-view at the very time when scientific poten-
tial for new drug development should give high
hopes. One can only hope that this opinion is wrong
(which is not very likely) or that the national offices
of health will realize that their actions will become
counter-productive in due course. Maybe it should
not be left to the pharmaceutical companies to
explain how the real situation is, maybe the inde-
pendent scientific community should raise its voice
a little louder, not to assist the industry, but to
contribute to the perspectives of health care.
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